Examples of 'placebo-treated' in a sentence
Meaning of "placebo-treated"
placebo-treated (noun) - Refers to the group of participants in a study or experiment who are given a placebo instead of an active treatment or intervention. This term is typically used in scientific or medical contexts to differentiate between groups receiving different types of treatments
How to use "placebo-treated" in a sentence
Basic
Advanced
placebo-treated
In placebo-treated patients heart rates remained unaffected.
No serious infections were reported in the placebo-treated patients.
No placebo-treated patients discontinued due to vomiting or dyspepsia.
Adverse reactions occurring only in placebo-treated patients are excluded.
Of placebo-treated patients had recovered at the data cutoff.
Cough occurred at a higher incidence than in placebo-treated patients.
No olaparib or placebo-treated patients discontinued due to diarrhoea.
No excess fluid was observed in any icodextrin or placebo-treated rabbits at necropsy.
The placebo-treated patient died of circulatory and respiratory insufficiency.
There were qualitatively more microthromboemboli in the brains of placebo-treated dogs.
No increases in placebo-treated subjects were reported.
The nature of the infections was generally similar in natalizumab - and placebo-treated patients.
A first group of untreated or placebo-treated tumor-bearing control animals acted as controls.
The word nocebo was created to define negative responses observed in placebo-treated groups.
In comparison, none of the placebo-treated patients withdrew due to somnolence and edema.
See also
From these data, means were calculated and compared to those of placebo-treated animals.
The changes were significantly worse in the placebo-treated patients than in the BCAA-treated patients.
The frequency of bleeding events did not differ between iloprost and placebo-treated patients.
All olanzapine and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors.
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints.
None of the placebo-treated subjects reached the AACE goal.
The type of infections reported was similar in both the Zenapax - and the placebo-treated groups.
Of placebo-treated patients.
The differences in heart rates between Celexa - and placebo-treated patients were statistically significant.
Sleep efficiencies of MA-1-treated subjects were compared with sleep efficiencies from placebo-treated subjects.
All olanzapine - and placebo-treated patients who experienced a cerebrovascular event had pre - existing risk factors.
Latent tuberculosis occurred in 1 placebo-treated patient.
FABLYN-treated and placebo-treated groups had similar incidences of endometrial hyperplasia and endometrial cancer see section 5.1.
Hypertrophied left and right ventricles in 8 placebo-treated rats were observed.
At week 24, all placebo-treated patients crossed over to infliximab induction.
HbA1c was stable in both duloxetine-treated and placebo-treated patients.
Finally, as with many trials, some placebo-treated participants showed improvement on the SRS.
K = Median of the baseline-corrected cell count value of placebo-treated group.
The results for the MSC and placebo-treated groups are shown in Figure 8.
Respiratory disorders occurred more frequently in abatacept-treated patients than in placebo-treated patients 10.8 % vs.
Compared to placebo-treated animals, the mortality rate in vaccinated animals was reduced by 59 %.
No such significant differences were observed in the placebo-treated control group . TABLE 2.
Closure in the placebo-treated group was linear, with a mean time to closure of 6.9 days.
Overall, 4 patients in Pertuzumab-treated group and 2 patients in the placebo-treated group experienced anaphylaxis.
For the placebo-treated subjects there was a slight increase in median uterine volume ( 10 % ) and fibroid volume 8.
IU / ml but consistently higher in the daclatasvir-treated patients than for placebo-treated patients in all subgroups.
A greater percentage of abatacept - than placebo-treated patients with COPD developed a serious adverse reaction 5.4 % vs.
Bone formation was observed in less than 12 % of placebo-treated wounds.
Patient-years for placebo-treated patients.
The incidence of hypersensitivity reactions was 1.1 % in both saxagliptin-treated patients and placebo-treated patients.
Further analysis of the MSWS-12 scores in placebo-treated subjects, is provided in Figure A4.
Adverse events resulted in treatment discontinuation in 16 % of cabozantinib-treated patients and in 8 % of placebo-treated patients.
However, DPD also fell in placebo-treated subjects.
Anti-dsDNA antibodies were newly detected in approximately 17 % of infliximab-treated patients compared with 0 % of placebo-treated patients.
The study found that on day 90, as compared to the placebo-treated group, there was.
